G1 Therapeutics buy Needham & Company LLC
Start price
20.04.23
/
50%
€2.73
Target price
20.04.24
€16.39
Performance (%)
39.05%
End price
21.04.24
€3.80
Summary
This prediction ended on 21.04.24 with a price of €3.80. The BUY prediction by Needham___Company_LL for G1 Therapeutics saw massive gains of 39.05%. Needham___Company_LL has a follow-up prediction for G1 Therapeutics where he still thinks G1 Therapeutics is a Buy. Needham___Company_LL has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| G1 Therapeutics | 14.761% | 14.761% | 50.949% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% |
Comments by Needham___Company_LL for this prediction
In the thread G1 Therapeutics diskutieren
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Ratings data for GTHX provided by MarketBeat
In the thread Trading G1 Therapeutics
Die von Needham___Company_LL gewählte maximale Laufzeit wurde überschritten